Albuterol in the treatment of acute respiratory distress syndrome: A meta-analysis of randomized controlled trials
10.5847/wjem.j.1920-8642.2015.03.001
- Author:
Ruo WU
1
;
Shi-Yun LIN
;
Hui-Min ZHAO
Author Information
1. Department of Emergency Medicine
- Publication Type:Journal Article
- Keywords:
Albuterol;
Acute respiratory distress syndrome;
Mortality;
Ventilator-free days
- From:
World Journal of Emergency Medicine
2015;6(3):165-171
- CountryChina
- Language:English
-
Abstract:
BACKGROUND: This meta-analysis of randomized controlled trials aimed to systematically evaluate the value of albuterol in the treatment of patients with acute respiratory distress syndrome (ARDS). DATA SOURCES: Randomized controlled trials on albuterol treatment of ARDS from its inception to October 2014 were searched systematically. The databases searched included: PubMed, Ovid EMBASE, Ovid Cochrane, CNKI, WANFANG and VIP. The trials were screened according to the pre-designed inclusion and exclusion criteria. We performed a systematic review and meta-analysis of the randomized controlled trials (RCTs) on albuterol treatment, attempting to improve outcomes, i.e. lowering the 28-day mortality and ventilator-free days. RESULTS: Three RCTs involving 646 patients met the inclusion criteria. There was no significant decrease in the 28-day mortality (risk difference=0.09;P=0.07,P for heterogeneity=0.22, I2=33％). The ventilator-free days and organ failure-free days were significantly lower in the patients who received albuterol (mean difference=-2.20;P<0.001,P for heterogeneity=0.49,I2=0％ and mean difference=-1.71,P<0.001,P for heterogeneity=0.60,I2=0％). CONCLUSIONS: Current evidences indicate that treatment with albuterol in the early course of ARDS was not effective in increasing the survival, but significantly decreasing the ventilator-free days and organ failure-free days. Owing to the limited number of included trails, strong recommendations cannot be made.
